We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

53 hedge funds and large institutions have $117M invested in Trevi Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

100% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 8

47% more funds holding

Funds holding: 36 → 53 (+17)

45% more capital invested

Capital invested by funds: $80.4M → $117M (+$36.3M)

8.9% more ownership

Funds ownership: 72.38% → 81.28% (+8.9%)

Holders
53
Holders Change
+17
Holders Change %
+47.22%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
16
Reduced
8
Closed
5
Calls
$47K
Puts
–
Net Calls
+$47K
Net Calls Change
+$133K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.42M
2
OM
Opaleye Management
Massachusetts
+$2.18M
3
State Street
State Street
Massachusetts
+$1.46M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.34M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.04M

Top Sellers

Rank Fund Capital Flow
1
FFM
Fairmount Funds Management
Pennsylvania
-$1.28M
2
Renaissance Technologies
Renaissance Technologies
New York
-$373K
3
MCM
MAI Capital Management
Ohio
-$166K
4
IAM
Innovis Asset Management
Illinois
-$111K
5
Millennium Management
Millennium Management
New York
-$110K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$27.2M – – –
FLSM
2
Frazier Life Sciences Management
California
$16.4M +$548K +217,500 +3%
RCMNY
3
Rubric Capital Management (New York)
New York
$13.6M – – –
FFM
4
Fairmount Funds Management
Pennsylvania
$12.4M -$1.28M -506,155 -9%
Viking Global Investors
5
Viking Global Investors
Connecticut
$10.5M – – –
VA
6
VR Adviser
New York
$8.18M +$938K +372,375 +12%
BlackRock
7
BlackRock
New York
$5.34M +$5.42M +2,152,616 +2,617%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.57M +$1.04M +413,511 +28%
OM
9
Opaleye Management
Massachusetts
$4.07M +$2.18M +865,700 +104%
MCM
10
MAI Capital Management
Ohio
$3.67M -$166K -65,763 -4%
SCM
11
Silverarc Capital Management
Massachusetts
$2.12M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.86M +$1.34M +530,528 +214%
State Street
13
State Street
Massachusetts
$1.63M +$1.46M +581,051 +584%
Northern Trust
14
Northern Trust
Illinois
$769K +$649K +257,374 +401%
BCM
15
Bridgeway Capital Management
Texas
$446K -$4.83K -1,919 -1%
TC
16
Tejara Capital
United Kingdom
$431K -$25.2K -9,991 -5%
JGC
17
J. Goldman & Co
New York
$330K +$123K +48,685 +55%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$315K +$297K +117,769 +835%
TCOT
19
Trust Company of Toledo
Ohio
$298K +$105K +41,857 +50%
Charles Schwab
20
Charles Schwab
California
$257K +$240K +95,150 +758%
PP
21
PFS Partners
New Jersey
$239K +$252K +100,000 New
WA
22
WealthTrust Axiom
Pennsylvania
$223K – – –
Renaissance Technologies
23
Renaissance Technologies
New York
$213K -$373K -148,100 -62%
N
24
Nuveen
North Carolina
$160K +$169K +66,935 New
Citadel Advisors
25
Citadel Advisors
Florida
$144K -$28.2K -11,202 -16%
1
2 3

TRVI Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2023, worth a combined $117M — up 45% from $80.4M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new TRVI positions and 5 closed out — a net gain of 17 holders — while 16 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $5.42M. The largest seller was Fairmount Funds Management, cutting an estimated $1.28M.

  • 53 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2023, up from 36 in Q1 2023.
  • Funds reported $117M of Trevi Therapeutics stock for Q2 2023, up 45% quarter-over-quarter.
  • 22 funds opened new Trevi Therapeutics positions in Q2 2023 and 5 closed out, a net change of +17 holders.
  • The largest Trevi Therapeutics buyer in Q2 2023 was BlackRock, an estimated $5.42M added.
  • The largest Trevi Therapeutics seller in Q2 2023 was Fairmount Funds Management, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2023.